Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $4,156 | 207 | 98.8% |
| Education | $52.23 | 3 | 1.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $725.10 | 42 | $0 (2024) |
| Avanir Pharmaceuticals, Inc. | $600.12 | 27 | $0 (2022) |
| Bayer Healthcare Pharmaceuticals Inc. | $485.39 | 18 | $0 (2024) |
| Arbor Pharmaceuticals, Inc. | $315.88 | 22 | $0 (2022) |
| GlaxoSmithKline, LLC. | $280.94 | 16 | $0 (2024) |
| Lilly USA, LLC | $218.61 | 10 | $0 (2024) |
| Allergan Inc. | $175.56 | 10 | $0 (2019) |
| Novo Nordisk Inc | $163.55 | 8 | $0 (2024) |
| PFIZER INC. | $155.47 | 7 | $0 (2023) |
| Dexcom, Inc. | $153.52 | 5 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $311.83 | 13 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($111.54) |
| 2023 | $725.33 | 30 | Dexcom, Inc. ($153.52) |
| 2022 | $456.00 | 19 | Bayer HealthCare Pharmaceuticals Inc. ($230.58) |
| 2021 | $420.11 | 17 | Bayer HealthCare Pharmaceuticals Inc. ($198.23) |
| 2020 | $370.81 | 25 | Arbor Pharmaceuticals, Inc. ($148.87) |
| 2019 | $670.65 | 32 | Avanir Pharmaceuticals, Inc. ($284.55) |
| 2018 | $603.68 | 38 | Avanir Pharmaceuticals, Inc. ($148.49) |
| 2017 | $649.41 | 36 | GlaxoSmithKline, LLC. ($115.25) |
All Payment Transactions
210 individual payment records from CMS Open Payments — Page 3 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 07/28/2022 | Lilly USA, LLC | EMGALITY (Drug), JARDIANCE | Food and Beverage | In-kind items and services | $29.93 | General |
| Category: Neuroscience | ||||||
| 07/21/2022 | PFIZER INC. | ELIQUIS (Drug), PAXLOVID | Food and Beverage | In-kind items and services | $25.92 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 07/14/2022 | Lilly USA, LLC | BAQSIMI (Drug), LYUMJEV | Food and Beverage | In-kind items and services | $20.98 | General |
| Category: Diabetes | ||||||
| 06/17/2022 | Bayer HealthCare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $32.92 | General |
| Category: Cardio-renal | ||||||
| 06/02/2022 | Avanir Pharmaceuticals, Inc. | Nuedexta (Drug) | Food and Beverage | In-kind items and services | $31.51 | General |
| Category: pseudobulbar affect (PBA) | ||||||
| 04/29/2022 | Bayer HealthCare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $27.92 | General |
| Category: Cardio-renal | ||||||
| 04/07/2022 | Astellas Pharma US Inc | Myrbetriq (Drug) | Food and Beverage | In-kind items and services | $20.54 | General |
| Category: Urology | ||||||
| 03/24/2022 | Arbor Pharmaceuticals, Inc. | Edarbi (Drug) | Food and Beverage | In-kind items and services | $23.72 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 03/11/2022 | Bayer HealthCare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $25.34 | General |
| Category: Cardio-renal | ||||||
| 02/03/2022 | Bayer HealthCare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $22.54 | General |
| Category: Cardio-renal | ||||||
| 02/03/2022 | Bayer HealthCare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $6.25 | General |
| Category: Cardio-renal | ||||||
| 01/03/2022 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | RELISTOR (Drug) | Food and Beverage | In-kind items and services | $23.50 | General |
| Category: Gastroenterology | ||||||
| 12/09/2021 | Bayer HealthCare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $18.54 | General |
| Category: Cardio-renal | ||||||
| 12/09/2021 | Bayer HealthCare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $5.50 | General |
| Category: Cardio-renal | ||||||
| 12/02/2021 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $21.71 | General |
| Category: ANTIBIOTIC | ||||||
| 11/11/2021 | Avanir Pharmaceuticals, Inc. | Nuedexta (Drug) | Food and Beverage | In-kind items and services | $22.20 | General |
| Category: pseudobulbar affect (PBA) | ||||||
| 11/04/2021 | Hikma Pharmaceuticals USA | Mitigare (Drug) | Food and Beverage | In-kind items and services | $15.88 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/30/2021 | Bayer HealthCare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $122.50 | General |
| Category: Cardio-renal | ||||||
| 09/23/2021 | Avanir Pharmaceuticals, Inc. | Nuedexta (Drug) | Food and Beverage | In-kind items and services | $22.69 | General |
| Category: pseudobulbar affect (PBA) | ||||||
| 09/17/2021 | Bayer HealthCare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $23.70 | General |
| Category: Cardio-renal | ||||||
| 08/19/2021 | Bayer HealthCare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $21.19 | General |
| Category: Cardio-renal | ||||||
| 08/19/2021 | Bayer HealthCare Pharmaceuticals Inc. | Kerendia (Drug) | Education | In-kind items and services | $6.80 | General |
| Category: Cardio-renal | ||||||
| 08/12/2021 | RedHill Biopharma Inc. | Movantik (Drug) | Food and Beverage | In-kind items and services | $14.50 | General |
| Category: Opioid Antagonist | ||||||
| 06/17/2021 | ARBOR PHARMACEUTICALS, INC. | Edarbi (Drug) | Food and Beverage | In-kind items and services | $23.83 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 05/21/2021 | Avanir Pharmaceuticals, Inc. | NUEDEXTA (Drug) | Food and Beverage | In-kind items and services | $24.88 | General |
| Category: pseudobulbar affect (PBA) | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 231 | 389 | $52,225 | $32,323 |
| 2022 | 7 | 247 | 427 | $64,975 | $38,559 |
| 2021 | 10 | 240 | 446 | $62,250 | $39,311 |
| 2020 | 10 | 246 | 605 | $74,875 | $43,767 |
All Medicare Procedures & Services
39 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 36 | 115 | $12,650 | $7,710 | 60.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 23 | 49 | $8,330 | $5,095 | 61.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 33 | 34 | $8,500 | $4,940 | 58.1% |
| 99497 | Advance care planning, first 30 minutes | Facility | 2023 | 37 | 66 | $6,600 | $4,185 | 63.4% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 31 | 31 | $4,185 | $4,101 | 98.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 18 | 34 | $3,740 | $2,254 | 60.3% |
| G0182 | Physician supervision of a patient under a medicare-approved hospice (patient not present) requiring complex and multidisciplinary care modalities involving regular physician development and/or revision of care plans, review of subsequent reports of patien | Office | 2023 | 13 | 20 | $4,000 | $1,619 | 40.5% |
| G0182 | Physician supervision of a patient under a medicare-approved hospice (patient not present) requiring complex and multidisciplinary care modalities involving regular physician development and/or revision of care plans, review of subsequent reports of patien | Facility | 2023 | 16 | 16 | $3,200 | $1,437 | 44.9% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 12 | 12 | $900.00 | $863.16 | 95.9% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 12 | 12 | $120.00 | $117.60 | 98.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 40 | 109 | $11,990 | $7,435 | 62.0% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 42 | 44 | $11,000 | $7,364 | 66.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 25 | 54 | $9,180 | $5,557 | 60.5% |
| G0182 | Physician supervision of a patient under a medicare-approved hospice (patient not present) requiring complex and multidisciplinary care modalities involving regular physician development and/or revision of care plans, review of subsequent reports of patien | Office | 2022 | 20 | 61 | $11,550 | $5,189 | 44.9% |
| 99497 | Advance care planning, first 30 minutes | Facility | 2022 | 43 | 71 | $8,200 | $4,682 | 57.1% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 29 | 29 | $3,915 | $3,861 | 98.6% |
| G0182 | Physician supervision of a patient under a medicare-approved hospice (patient not present) requiring complex and multidisciplinary care modalities involving regular physician development and/or revision of care plans, review of subsequent reports of patien | Facility | 2022 | 29 | 29 | $5,700 | $2,662 | 46.7% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 19 | 30 | $3,440 | $1,810 | 52.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 46 | 161 | $17,745 | $12,255 | 69.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 39 | 96 | $16,320 | $10,278 | 63.0% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 22 | 23 | $5,750 | $3,642 | 63.3% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2021 | 26 | 26 | $3,510 | $3,510 | 100.0% |
| G0182 | Physician supervision of a patient under a medicare-approved hospice (patient not present) requiring complex and multidisciplinary care modalities involving regular physician development and/or revision of care plans, review of subsequent reports of patien | Office | 2021 | 18 | 36 | $6,810 | $3,174 | 46.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 13 | 23 | $3,680 | $2,032 | 55.2% |
| G0182 | Physician supervision of a patient under a medicare-approved hospice (patient not present) requiring complex and multidisciplinary care modalities involving regular physician development and/or revision of care plans, review of subsequent reports of patien | Facility | 2021 | 14 | 15 | $3,000 | $1,347 | 44.9% |
About Dr. Jo Pullen, MD
Dr. Jo Pullen, MD is a Geriatric Medicine healthcare provider based in Los Angeles, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/03/2006. The National Provider Identifier (NPI) number assigned to this provider is 1225005663.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jo Pullen, MD has received a total of $4,208 in payments from pharmaceutical and medical device companies, with $311.83 received in 2024. These payments were reported across 210 transactions from 31 companies. The most common payment nature is "Food and Beverage" ($4,156).
As a Medicare-enrolled provider, Pullen has provided services to 964 Medicare beneficiaries, totaling 1,867 services with total Medicare billing of $153,960. Data is available for 4 years (2020–2023), covering 39 distinct procedure/service records.
Practice Information
- Specialty Geriatric Medicine
- Location Los Angeles, CA
- Active Since 03/03/2006
- Last Updated 03/07/2023
- Taxonomy Code 207RG0300X
- Entity Type Individual
- NPI Number 1225005663
Products in Payments
- XIFAXAN (Drug) $626.49
- NUEDEXTA (Drug) $601.44
- Kerendia (Drug) $485.39
- Dexcom G6 Transmitter (Medical Supply) $153.52
- Edarbi (Drug) $148.25
- RELISTOR (Drug) $140.44
- Edarbyclor (Drug) $136.00
- LONHALA MAGNAIR (Drug) $132.82
- TRELEGY ELLIPTA (Drug) $127.14
- BREO (Drug) $112.15
- CHANTIX (Drug) $105.58
- Tymlos (Biological) $92.31
- ELIQUIS (Drug) $90.89
- JARDIANCE (Drug) $77.14
- Nuedexta (Drug) $76.40
- AMYVID (Drug) $66.64
- Ozempic (Drug) $60.83
- LINZESS (Drug) $60.72
- NAMZARIC (Drug) $59.27
- MYRBETRIQ (Drug) $46.72
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Geriatric Medicine Doctors in Los Angeles
James Kirkland, M.d, M.D
Geriatric Medicine — Payments: $34,497
Arman Hekmati, M.d, M.D
Geriatric Medicine — Payments: $14,694
Dr. Dong Lee, M.d, M.D
Geriatric Medicine — Payments: $7,236
Mr. Gregory Taylor, M.d, M.D
Geriatric Medicine — Payments: $6,139
Dr. Azmy Ghaly, Medical Doctor, MEDICAL DOCTOR
Geriatric Medicine — Payments: $4,722
Joshua Chodosh, Md, MD
Geriatric Medicine — Payments: $3,656